The antitumoral activity of 13-demethyl or 13-substituted all-trans retinoic acid (ATRA) and 9-cis retinoic acid (9CRA) was tested using the myeloid leukemia cell line HL-60. Cell proliferation, differentiation and apoptosis were evaluated by flow cytometry and DNA fragmentation assay. The ability to bind to human RXRa a and to activate either human retinoic acid response element (RARE)-mediated gene expression or rat CRABPII retinoid X response element (RXRa a)-mediated gene expression were determined using luciferase reporter plasmids. In terms of the magnitude of the regulatory activity for the proliferation and differentiation of HL-60 cells, the compounds ranked as follows: ATRAϾ13-ethyl ATRAϾ13-demethyl ATRAϾ13-phenylethyl ATRAϾ13-propyl ATRAϾ13-butyl ATRA (ATRA analogues) and 9CRAϾ13-ethyl 9CRAϾ13-demethyl 9CRAϾ13-propyl 9CRAϾ13-phenetyl 9CRAϾ13-butyl 9CRA (9CRA analogues). Regarding the magnitude of the apoptosis-inducing activity, the order was: 9CRAϾ13-ethyl 9CRAϾ13-demethyl 9CRA, with ATRA and its analogues and the other 9CRA analogues virtually inactive. Similar trends were observed in binding affinity for RXRa a and transactivation activity toward RARE-or RXRE-mediated gene expression. The results clearly indicate that the presence of a methyl group at C-13 is essential for the antitumoral activity of ATRA and 9CRA, and that bulky substituents exceeding two carbon atoms or the absence of substitution at position 13 significantly reduce the binding affinity for RAR and RXR, leading to a decreased RAR/RARE and/or RXR/RXRE-mediated gene expression.
Retinoids, namely all-trans retinoic acid (ATRA) and its natural or synthetic analogues, have potential chemopreventive and therapeutic applications in the field of dermatology and oncology due to their potent antiproliferative and differentiation-inducing activities towards many benign and malignant tumors. In particular, ATRA has been shown to be a potent inducer of the differentiation of acute promyelocytic leukemia (APL) blasts and is widely used with chemotherapeutic drugs to treat APL. 1, 2) However, the clinical use of retinoids is largely restricted for the several reasons. The doses needed for successful treatment often cause hypervitaminosis A syndrome and some patients with APL eventually relapse with the development of resistance to ATRA. In attempts to overcome these problems, numerous retinoids have been synthesized and their antitumoral activity has been evaluated in the search for compounds with greater efficacy and fewer side-effects. However, these efforts have been only partially successful to date, and the search for retinoids exhibiting a better therapeutic index continues. Although the precise molecular mechanisms underlying ATRA-induced growth inhibition and differentiation remain unclear, it is well established that in many cells, these activities involve modulations of gene expression and are mediated by binding to the retinoic acid receptors (RARs) and/or the nuclear retinoid X receptors (RXRs). It has been shown that RARs are activated by many bioactive compounds including ATRA and 9CRA, while RXRs are activated only by 9CRA. 3, 4) The leukemic cell lineage HL-60 is considered a good model for the study of antiproliferative and prodifferentiating effects of retinoids. 5) In the presence of different agents, particularly retinoids, HL-60 cells can be induced to differentiate into monocytes or granulocytes.
Here we examined the effect of 13-demethyl or 13-substituted ATRA and 9CRA on the proliferation, differentiation and apoptosis of HL-60 cells based on flow cytometry, cell surface antigen expression and DNA fragmentation. We have also evaluated the ability of these compounds to bind RXRa and activate RARE-or RXRE-mediated gene expression using luciferase reporter plasmids.
MATERIALS AND METHODS

Materials
All-trans retinoic acid (ATRA), 9-cis retinoic acid (9CRA), 13-demetyl or 13-substituted analogues of ATRA and 9CRA were synthesized by Wada et al. 6, 7) All twelve analogues tested are shown in Fig. 1 . The analogues were dissolved in absolute ethanol as stock solutions at 10 Ϫ3 M and stored at Ϫ35°C protected from light. All other reagents were of the highest analytical grade commercially available.
HL-60 Cells and Synchronization of Cell Cycle at S Phase Using Excess Amounts of Thymidine HL-60 cells were maintained in continuous culture in RPMI-1640 medium (Nissui Seiyaku Co., Ltd., Tokyo, Japan) supplemented with 10% dextran-coated charcoal-treated fetal calf serum (FCS) (Gibco BRL, Grand Island, NY, U.S.A.), and kanamycin (0.06 mg/ml) (Sigma, St. Louis, MO, U.S.A.) at 37°C in a humidified atmosphere of 5% CO 2 in air. The doubling time of HL-60 cells was approximately 24 h. For synchronization at S phase, cells (4ϫ10 5 cells/ml) were cultured in 30 ml of RPMI-1640 medium supplemented with 2.5 mM thymidine. After two washes with Ca, Mg-free phosphate-buffered saline (PBS) [PBS(Ϫ)], the synchronization of the cell cycle was repeated in the same manner, and the cells thus obtained were used in the biological assays.
Flow Cytometry Cells (10 5 cells/well) were placed in 24-well tissue culture plates and cultured for 3 d with retinoids (10
Ϫ10
-10 Ϫ6 M) in RPMI-1640 medium at 37°C in a humidified atmosphere of 5% CO 2 in air. To reduce the effects of contact inhibition, control cells were adjusted to 60 to 70% confluency at the time of the FACS analysis. Each group of cells was collected in PBS(Ϫ). Then, the cells were resuspended in PBS(Ϫ) containing 0.2% Triton-X and 1 ml RNase, and incubated at 37°C for 1 h. Cells were washed with PBS(Ϫ) and incubated with 0.5 ml of DNA-staining solution containing propidium iodide (50 mg/ml) at 4°C for 20 min. The cells were analyzed with a flow cytometer equipped with an argon laser (488 nm, Becton Dickinson FACScan TM ) and the cell cycle distribution was analyzed using ModiFiT LT (Verity).
Cell Surface Antigen Expression Analysis Cells (10 5 cells/well) were placed in 24-well tissue culture plates, and cultured for 3 d in RPMI-1640 medium with retinoids (10
-10 Ϫ6 M) under the same conditions as described for the flow cytometry. Each group of cells was then collected and washed with PBS(Ϫ) once. Next, the cells (2ϫ10 5 cells) were resuspended in 100 ml of diluent solution containing 1% bovine serum albumin (BSA) and 1% sodium azide and incubated with 10 ml of human monoclonal FITC-conjugated CD11b antibody and CD14 antibody (Sigma) for 30 min at room temperature. The cells were washed once with diluent solution and then fixed in 300 ml of PBS(Ϫ) containing 2% paraformaldehyde. Fluorescence was detected on a Becton Dickinson FACScan TM at an excitation wavelength of 490 nm and emission wavelength of 520 nm. Results were recorded as the mean fluorescence index, which is the product of the % fluorescence and the mean fluorescence intensity, with 10 4 cells being counted per treatment.
DNA Fragmentation Assay
For the assessment of quantitative DNA fragmentation (laddering), DNA was isolated from cells of each culture, and examined for fragmentation. DNA was electrophoresed in a 2% agarose gel that was stained with ethidium bromide for observation under ultraviolet light.
Transfection and Luciferase Activity Assay Human osteosarcoma MG-63 cells, which are positive for RXR gene expression, were maintained in Dulbecco's modification Eagle's medium (Gibco BRL) supplemented with 1% penicillin, 1% streptomycin and 10% dextran-coated charcoaltreated FCS (Gibco BRL). The day before transfection, cells were seeded on six-well culture plates at a density of 2ϫ10 5 cells per well so they reached confluence the day of transfection. Cells were transfected with 1.0 mg of a one-hybrid plasmid (pM vector, Promega Corp., Madison, WI, U.S.A.) containing a human RXR cDNA connected with a yeast GAL4 DNA-binding domain cDNA (GAL-DBD), 0.5 mg of luciferase reporter plasmid (pGVP2 vector, Toyo Ink Co., Ltd.) containing a GAL-4 binding site (GAL-BS), and a pRL-CMV vector as an internal control using the Tfx-50 reagent (Promega Corp.).
HepG2 cells were maintained in minimum essential medium containing 10% dextran-coated charcoal-treated fetal bovine serum, 1% non-essential amino acids, 1% sodium pyruvate, penicillin (100 IU/ml) and streptomycin (100 mg/ml). The day before transfection, cells were seeded on six-well culture plates at a density of 2ϫ10 5 cells per well so that they were confluent the day of transfection. The retinoid-responsive luciferase reporter constructs human RARb-RARE3-SV40-Luc and rat CRBPII-RXRE-SV40-Luc were generated by cloning three copies of the retinoic acid response element (RARE) from the RARb promoter (Ϫ59/Ϫ33: GGGTAAAGTTCACCGAAAGTTCACTCG) or the RXRE from the rat CRBPII promoter (Ϫ639/Ϫ605: GCTGTCACAGGTCACAGGTCACAGGTCACAGTTCA) in the pGL3 vector. 8, 9) The pRL-CMV vector was an internal control using the Tfx-50 reagent. After transfection, the cells were incubated with retinoids (10 Ϫ6 M) for 2 d. Luciferase activity of the cell lysates was measured with a luciferase assay system (Toyo Ink Co., Ltd.), according to the manufacture's instructions. Transactivation determined from the luciferase activity was standardized with the luciferase activity of the same cells measured with the Sea Pansy luciferase assay system as a control (Toyo Ink Co., Ltd.) Each set of experiments was repeated at least three times, and the results are presented in terms of fold induction as meansϮS.E.
Statistical Analysis Statistical significances were determined using Student's t-test and expressed as meansϮS.E. ATRA and 9CRA have been shown to induce cell cycle arrest at G0/G1 in benign and malignant tumor cells including HL-60 cells. 10, 11) To examine the antiproliferative effect on HL-60 cell growth, we measured the cell cycle phase distribution of HL-60 cells treated with increasingly higher concentrations of either ATRA, 9CRA or their analogues. After incubation with ATRA or its analogues for 3 d, all the cells were stained with propidium iodide. The results are depicted in Fig. 2 . The percentages of HL-60 cells arrested at the G0/G1 phase increased significantly from 46.3% (vehicletreated cells) to 74.9% (10 Ϫ6 M ATRA-treated cells), while those arrested at the S phase decreased significantly from 45.3% (vehicle-treated cells) to 15.7% (10 Ϫ6 M ATRA-treated cells). ATRA analogues also caused HL-60 cells to arrest at G0/G1 and a decrease in cells in the S phase in a dose-dependent fashion. In order of the magnitude of the cell cycle regulatory activity, the ATRA analogues ranked as follows: ATRAϾAT102ϾAT100ϾAT107ϾAT103ϾAT104. Similarly, after incubation with 9CRA or its analogues, the percentages of HL-60 cells arrested at G0/G1 increased significantly from 49.0% (vehicle-treated cells) to 76.3% (10 Ϫ6 M 9CRA-treated cells), while those arrested at the S phase decreased significantly from 41.5% (vehicle-treated cells) to 13.3% (10 Ϫ6 M 9CRA-treated cells) as shown in Fig. 3 . According to the magnitude of the cell cycle regulatory activity, 9CRA and its analogues ranked as follows: 9CRAϾ9C102Ͼ 9C100Ͼ9C103Ͼ9C107, with 9C104 virtually inactive.
RESULTS
Effects of 13-
Effects of ranked as follows: ATRAϾAT102ϾAT100ϾAT107ϾAT103Ͼ AT104 and 9CRAϾ9C102Ͼ9C100Ͼ9C103Ͼ9C107. 9C104 did not induce CD11b antigen expression at any dose tested.
Effects of 13-Demethyl or 13-Substituted Analogues of ATRA and 9CRA on Apoptosis of HL-60 Cells As shown in Fig. 5 , none of the ATRA analogues exhibited apoptosis-inducing activity. However, 9CRA, 9C102 and 9C100 significantly induced apoptosis in HL-60 cells. Figure  6 shows the results of the agarose gel electrophoresis of the DNA samples from HL-60 cells treated with increasingly higher concentrations of 9CRA and its analogues for 3 d. 9CRA and 9C102 induced DNA fragmentation in the cells in a dose-dependent fashion, while 9C100, 9C103, 9C107 and 9C104 were inactive at all concentrations tested.
Transactivation of 13-Demethyl or 13-Substituted Analogues of ATRA and 9CRA on Target Genes To obtain insights into the molecular mechanisms by which ATRA, 9CRA and their analogues modulate HL-60 cell proliferation, differentiation and apoptosis, we examined their transactivation activity toward target genes. Figsures 7A and B show the binding affinity of ATRA, 9CRA and their analogues at 10 Ϫ6 M for human RXRa expressed in transfected MG-63 cells. As expected from the apoptosis-inducing activity, none of the ATRA analogues exhibited the ability to bind to RXRa, although ATRA itself possesses weak affinity for RXRa. In contrast, 9CRA, 9C102 and 9C100 which were shown to be potent inducers of differentiation and apoptosis, exhibited high binding affinity for RXRa. 9C103, 9C104 and 9C107 did not bind to RXRa at any concentrations tested (Fig. 8) .
Next, we assessed the transactivation activity of ATRA, 9CRA and their analogues at different concentrations toward a human RARb gene promoter containing three RAREs in transfected HepG2 cells. As shown in Figs. 9A and B, in terms of the magnitude of the transactivation activity, ATRA and its analogues ranked as follows: ATRAϾAT102Ͼ AT100ϾAT107ϾAT103ϾAT104, while for 9CRA and its analogues, the order was 9CRAϾ9C102Ͼ9C100Ͼ9C103ϭ 9C107. 9C104 did not exhibit transactivation activity at any concentrations tested. The result correlated well with the result for prodifferentiating activity shown in Fig. 2 . The results of the transactivation activity of ATRA, 9CRA and their analogues at 10 Ϫ6 M toward a rat CRABPII gene including RXRE in transfected HepG2 cells are shown in Fig. 10 . 9CRA and 9C102 were found to be effective in transactivating the CRABPII RXRE gene expression whereas other The cells were transfected with an expression plasmid containing a human RXRa cDNA connected with GAL-DBD, a Luciferase reporter plasmid containing GAL-BS, and a pRL-CMV vector as an internal control. After 2 d of culture with the compounds, cell lysates were prepared and light production from luciferase was measured as described in Materials and Methods. Luciferase activity induced by ATRA (A), 9CRA (B) and the analogues in MG-63 cells was quantified and represented as fold induction as compared with luciferase activity observed in the control cells. Results represent the means of three experiments (columns) and standard errors (vertical bars) at 10 Ϫ6 M. This system enabled us to assess the direct RXRa-mediated transcriptional activity of the compounds in the cells. In this system, RXRa bound to the derivative directly induced an increase in luciferase activity without interaction with RXRE. * * * pϽ0.001. 
DISCUSSION
In this study, we examined the regulatory activities of 13-demethyl or 13-substituted analogues of ATRA and 9CRA toward the proliferation, differentiation, and apoptosis of HL-60 cells. Our results clearly indicate that in both series of analogues, the replacement of the methyl group at C-13 with a hydrogen, ethyl, propyl, butyl or phenylethyl group induces a decrease or loss of these biological activities. The influence of such modifications on the side-chain was much more prominent in the 9CRA analogues than ATRA analogues, probably making it more difficult to bind to nuclear receptors, RXR and RAR. Demethylation and substitutions at position 13 of ATRA significantly reduced the potency to regulate cell proliferation and differentiation presumably due to a decrease in the transactivation activity through a RAR/RARE signaling pathway. However, these analogues were still biologically active at the concentrations tested. In contrast, the same modifications at position 13 of 9CRA remarkably reduced or diminished the ability to regulate the proliferation and differentiation of HL-60 cells, apparently due to a severe decrease in the binding affinity for RXR and incomplete RXR/RXRE-mediated signaling. Based on these findings, it is conceivable that the presence of the methyl group at C-13 of ATRA and 9CRA is important for the regulation of proliferation and differentiation of HL-60 cells and around the C-13 methyl group there lies a large enough cavity to adopt alkyl groups exceeding two carbon atoms or a bulky substitute, a phenylethyl group, in the RAR molecule, while the corresponding cavity in the RXR molecule may be much smaller and can adopt only a methyl or ethyl group. Danshina et al. 13, 14) reported that the introduction at position 13 of the chromophore of hydrocarbon substituents bulkier than that of the natural bacteriorhodopsin diminished the amplitudes of the electric photoresponses. Furthermore, bulky substituents or an absence of substitution at position 13 of retinals decelerated the relaxation of M-inermediates and disturbed 13-cis-to all-trans-isomerization. Thus, in bacteriorhodopsin, the presence of the methyl group at position 13 is essential for the light-driven proton transport and these previous findings are consistent with our results of the 9CRA analogues binding to the RXRa molecule.
It has been well documented that ATRA is a potent inhibitor and inducer of proliferation and differentiation of HL-60 cells due to its high binding affinity for RAR, while its ability to induce apoptosis is very weak because of its low affinity for RXR. In contrast, 9CRA is a potent inhibitor and inducer of proliferation, differentiation and apoptosis of HL-60 cells due to its high binding affinity for both RAR and RXR. The present results were well consistent with previous findings. Among ATRA, 9CRA and their analogues, 9CRA was the most potent retinoid in terms of inducing in differentiation and apoptosis of HL-60 cells probably due to its high binding affinity for RXR along with relatively high affinity for RAR. The 13-Ethyl analogue, 9C102, and 13-demethyl analogue, 9C100, both possess relatively high binding affin- ity for RXRa and for RAR, although a RAR binding assay was not performed, and therefore, it seems that they can exhibit significant differentiation-inducing activity in HL-60 cells (Fig. 4B ). Based on these findings, it is suggested that RAR can recognize precisely the structural difference between an ethyl group and a hydrogen at position 13 of ATRA and 9CRA. Nagy et al. 15) previously reported that ligand-induced activation of the RAR moiety in the RAR/RXR heterodimer is sufficient to induce the differentiation of HL-60 cells, but ligand-induced activation of the RXR moiety is not sufficient to induce differentiation, although it may potentiate cell differentiation mediated by RAR binding. Based on these findings, it has been postulated that the differentiation of HL-60 cells can be controlled by synthetic retinoids possessing the ability to regulate a RAR signaling or a RXR signaling, selectively. Am 80, 16) an aromatic amide of retinoic acid, has been shown to bind to and activate RAR selectively. HX600, 17) a dibenzodiazepine derivative, has been shown to be a RXR selective agonist and also exhibits synergistic activity with RAR ligands, although HX600 itself can not activate RAR/RXR heterodimers. In this study, we did not succeed in finding a RXR-selective agonist among the 13-demethyl or 13-substituted analogues of ATRA and 9CRA.
HL-60 cells not only differentiate but also are capable of undergoing apoptosis in response to retinoic acid. Ligandevoked activation of endogenous RAR is sufficient to induce differentiation of the HL-60 cells but the induction of apoptosis requires the activation of endogenous RXR. 15) In our study, 9CRA induced apoptosis in HL-60 cells. Previous studies indicated that compounds that activate both RAR and RXR could induce apoptosis. In this study, 9C102 and 9C100 were able to induce apoptosis in HL-60 cells. Their apoptosis-inducing activity was very weak and only seen at low concentrations that were not high enough to induce HL-60 cell differentiation and to activate RAR or RXR-mediated gene expression. The molecular mechanisms underlying the induction of apoptosis by 9C102 and 9C100 remain unclear, however, and it is conceivable that their apoptosis-inducing activity is independent from a RAR-or RXR-mediated signaling pathway.
In summary, we have evaluated for the first time the biological effects of 13-demethyl or 13-substituted analogues of ATRA and 9CRA on the proliferation, differentiation, and apoptosis of HL-60 cells along with transactivation activity in transfected MG-63 cells. These analogues exhibited unique activity profiles depending upon the substituent at C-13. Our results suggest that the presence of a methyl group at C-13 is essential for the antitumoral activities of ATRA and 9CRA, and that a bulky substituent exceeding two carbon atoms or the absence of a substitution at position 13 significantly reduced their binding affinity for RAR or RXR, leading to a decreased RAR/RARE and /or RXR/RXRE-mediated gene expression.
These findings should provide useful information for the development of analogues of ATRA and 9CRA for biomedical applications.
